Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 11/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | DDX3X | O00571 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313256 | 1.00 | PRMT3 (0.40) | PRMT3ROCK2ROCK1HRH3GBA1 | |
| SCHEMBL3315427 | 0.93 | HRH3 (0.45) | PRMT3ROCK2ROCK1HRH3GBA1 | |
| SCHEMBL3316815 | 0.90 | IMPDH2 (0.42) | PRMT3ROCK2ROCK1IMPDH2DDX3X | |
| SCHEMBL3318830 | 0.88 | PRMT3 (0.41) | PRMT3ROCK2ROCK1 | |
| SCHEMBL3318835 | 0.88 | PRMT3 (0.41) | PRMT3ROCK2ROCK1 | |
| SCHEMBL3833348 | 0.84 | ROCK2 (0.43) | PRMT3ROCK2ROCK1 | |
| SCHEMBL3316796 | 0.83 | ROCK2 (0.54) | PRMT3ROCK2ROCK1 | |
| SCHEMBL3316792 | 0.83 | ROCK2 (0.54) | PRMT3ROCK2ROCK1 | |
| SCHEMBL3837972 | 0.82 | ROCK2 (0.43) | PRMT3ROCK2ROCK1IMPDH2CYP3A4 | |
| SCHEMBL3315792 | 0.81 | ROCK2 (0.58) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | PRMT3 716/4885ROCK2 6/4885ROCK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.